
("IQ-AI" or the "Company")
Imaging Biometrics Announces Expanded Access Program for Oral Gallium Maltolate
Company initiating program based on phase 1 tolerability and safety results
Imaging Biometrics, LLC (IB), a wholly owned subsidiary of
EAPs are regulated by the
"Considering the dismal prognosis of high-grade brain tumors, and following the encouraging safety profile and tolerance demonstrated in the ongoing phase 1 clinical trial at the
--ENDS-
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
Tel: 020 7469 0930 |
Tel: 020 7220 9797 |
About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the